Mohd Ashhad: The Science Behind a Safe Transfusion
Mohd Ashhad, Medical Laboratory Technologist at Blood Bank, shared a post on LinkedIn։
”A Routine Crossmatch, But Never Just a Routine Job
Today in the blood bank, I worked on an interesting transfusion case.
The patient’s blood group was AB Positive, and an AB Negative red cell unit was selected for transfusion. Although the ABO groups were compatible, we still needed to confirm that the selected donor unit was serologically compatible with the patient.
That’s where crossmatching becomes important.
Crossmatch performed:
Gel Card / Column Agglutination Technique – AHG phase
The patient’s plasma was tested against the donor red cells. After the required incubation and centrifugation steps, the reaction pattern in the gel column was carefully observed.
Result: Compatible
There was no significant agglutination observed, with the red cells forming a compact cell button at the bottom of the microtube.
Why is crossmatching important?
Blood grouping tells us the patient’s ABO and Rh(D) type, but it doesn’t tell the complete story. A patient may have clinically significant antibodies against red-cell antigens that are not detected simply by ABO/Rh typing.
Crossmatching helps us check whether the specific donor red cells selected for that patient are compatible before transfusion.
For me, this is one of the most important parts of blood bank work. A small gel card may look simple, but behind every result there is careful testing, observation, documentation, and responsibility.
Every compatible unit is more than a laboratory result—it is one step toward a safe transfusion.”
Stay updated with Hemostasis Today.
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution
-
Oct 12, 2026, 07:39Emmanuel J Favaloro: 100 Years of von Willebrand Disease and the Importance of Local Diagnosis and Management
-
Oct 12, 2026, 07:39Post-Stroke Fatigue Trajectories – 38% Recovered at 12 Months, While 16% Developed New Fatigue – International Journal of Stroke